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ABSTRACT
Background: Several studies have shown that 
atherosclerosis underlying processes of Cardiovascular 
disease (CVD), increased in rheumatoid arthritis 
(RA) and occurred early (premature). The cause of 
accelerated atherosclerosis in RA are still unknown. 
Adipokines have known that the adipokines play a role 
in the pathophysiology of RA and CVD. Accumulation of 
visceral fat associated with dysregulation of adipokines 
that influence the development of the atherosclerotic 
and disruption plaque. Obesity and pathological changes 
in fat mass and fat dysfunction as well as a change in 
the pattern of secretion of proinflammatory adipokines, 
may have a correlation between heart disease and 
rheumatic diseases. Adiponectin is one of the most 
widely-studied adipokines. In RA, adiponectin is 
involved in the pathophysiology of RA that produces of 
various proinflammatory and prodestructive molecules. 
So far, adiponectin has been known to provide anti-
atherosclerotic effects in patients with non-RA. But, 
several recent studies in RA patients get opposite 
results in which increased levels of adiponectin are 
associated with increased prevalence of atherosclerosis. 
The effect of adiponectin on atherosclerosis in patient 
with RA is still unknown. 
Objective: to determine the relationship of adiponectin 
with atherosclerosis in patients with rheumatoid 
arthritis.
Methods: This is a cross-sectional study conducted 
on outpatients of the rheumatology clinic at Cipto 
Mangunkusumo General Hospital from January until 
April, 2013. Subjects consisted of 50 patients were 
diagnosed based on ACR 1987/EULAR 2010 criteria. The 
collection of data obtained by consecutive sampling and 
evaluated the patients’ medical data that included age, 
long-suffering of RA, body mass index (BMI), lipid profile, 
rheumatoid factor levels, levels of anti-cyclic citrullinated 
peptide (anti-CCP), C-reactive protein (CRP), erythrocyte 
sedimentation rates (ESR), blood pressure, fasting 
blood glucose, 2 hour post prandial blood glucose, ECG, 
examination of serum adiponectin levels and bilateral 
carotid ultrasound to measure the carotid artery intima 
media thickness.
Results: From the results of the 50 patients studied, 
obtained 28 (56%) of patients had increased levels 
of adiponectin. Atherosclerosis was found in 13 
(26%) subjects. The median value was 9.46 μg / ml 
with the lowest levels of 4 μg/ml and the highest 
levels of 24μg/ml. The Spearman’s test showed no 
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significant correlation between adiponectin serum and 
atherosclerosis in patients with RA (p = 0706 and r 
= 0.055). The analysis results of the correlation of 
adiponectin with atherosclerosis based on age, disease 
duration, ESR, rheumatoid factor, DAS 28, CRP, BMI, 
dyslipidemia showed no significant correlation.
Conclusion :  From this study, researchers found no 
statistically significant correlation between adiponectin 
levels with marker of atherosclerosis (CIMT) in patients 
with rheumatoid arthritis
Keywords  : Adiponectin, Atherosclerosis
Rheumatoid arthritis (RA) is a chronic systemic 
infl ammatory disease characterized by the 
involvement of articular and extra-articular. 
Cardiovascular disease (CVD) is the most important 
cause of mortality and morbidity of patients with 
RA.1 CVD causes almost 50% to more deaths in 
patients with RA.2  Several studies have shown 
that atherosclerosis  underlying processes of CVD, 
increased in RA and occured early (premature). But 
the cause of accelerated atherosclerosis in RA are 
still unknown. The increased risk of CVD in RA 
can not be fully explained by traditional risk factors 
such as age, sex, smoking, hypertension or type 2 
diabetes (DM).3
In contrast to the general population, the risk 
of CVD in patients with RA particularly elevated 
in younger patients and female gender. Low body 
mass index (<20 kg/m2) was also associated with 
a higher cardiovascular mortality. This may be 
correlated with increased infl ammatory cytokines 
leads to a catabolic process.1
It remains unclear how the traditional risk 
factors interact with non-traditional rial factors to 
increase CVD in RA. However, some traditional 
risk factors, such as: men, sex, smoking and 
previous cardiovascular events, seems to have a 
relationship with the occurrence of CVD in patients 
with RA, but its contribution to the rate of CVD 
seems weak.4 
In addition to traditional risk factors, chronic 
systemic infl ammation has been shown to 
be an important factor in the development of 
atherosclerosis. Increased systemic infl ammation 
in patients with RA is one of the non-traditional 
factors that will increase the cardiovascular risk 
in RA.5 RA is a prototype of a chronic systemic 
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infl ammatory disease. And interestingly, there are similarities 
between the infl ammatory pathways  in atherosclerosis and 
RA.1
Although traditional risk factors are also involved in the 
pathogenesis of cardiovascular disease in patients with RA, 
but does not fully explain how the increased cardiovascular 
risk in this population. Classical risk factors such as obesity 
might explain the increased risk of CVD in patients with 
RA.6 It is well known that adipokines play a role in the 
pathophysiology of RA and CVD. Visceral fat accumulation 
associated with dysregulation of adipokines that infl uence the 
development of atherosclerotic and disruption plaque. Obesity 
and pathological changes in fat mass and fat dysfunction as 
well as a change in the pattern of secretion of proinfl ammatory 
adipokines, could be one of the link between heart disease and 
rheumatic diseases. Indeed, the incidence of CVD is increased 
in obese individuals with rheumatic disorders.7
Since the discovery of leptin in 1994, adipose tissue is no 
longer considered as a passive reservoir for storage energy.8 
Adipose tissue is an endocrine and metabolic organ that is 
very active and produce large amounts of bioactive peptides.8,9 
These molecules known as adipokines and substantially can 
modulate the metabolic cardiovascular risk factors including 
insulin resistance and atherogenesis, and infl ammatory  and 
immune respons. Leptin and adiponectin are the most studied 
adipokines.8
At the individual non-RA, adiponectin is anti-infl ammatory, 
anti-atherogenic, anti-diabetic,11, 12,13 repair and production of 
metabolic risk decrease with increasing adiposites.8, 10 High 
levels adiponectin are favorable factor because it will decrease 
the progression of atherosclerosis.14
The above fi ndings are very opposite, considering the 
increased adiponectin level in RA, while the incidence 
of atherosclerosis in RA also increased. In contrast to the 
properties of adiponectin as an anti-infl ammatory in a non-
RA population. In contrast to RA,  adiponectin is involved 
in the pathophysiology of RA, which produce a variety of 
proinfl ammatory and prodestructive molecule.8,15-18 Most 
studies in patients with RA have shown an increase in the 
serum concentration of adiponectin, and adiponectin is also 
produced in the infl ammed joints.8,15,19 Several studies have 
also shown that adiponectin is involved in the development 
of RA.8,15-18,20,21 These fi nding support the involvement of 
adiponectin in the immune response in RA. Adiponectin may 
play a role in the pathophysiology of rheumatoid arthritis 
that adiponectin can be a potential new therapeutic targets by 
performing inhibition of adiponectin.22
Is the RA could modify the effect of adiponectin on risk 
of atherosclerosis, is currently unknown. Therefore, this 
study required for the management of RA and inhibition of 
adiponectin on the possible use of RA (as a new therapeutic 
target),18 so that can explain how the inhibitory effect of 
adiponectin on cardiovascular risk in patients with RA. 
Adiponectin has anti-infl ammatory effects on blood vessels 
and on metabolic pathways and is a cardiovascular protective 
factor. Therefore, when inhibition therapy of adiponectin is 
done systematically, may provide cardiovascular consequences 
unintended opposite. Giving inhibitor of adiponectin through 
intra-articular pathways is more advisable because theoretically 
it can limit the proinfl ammatory effects of adiponectin on the 
joints but do not eliminate the anti-infl ammatory effects on 
blood vessels and cardiovascular.23 
Carotid Intima-Media Thickness (CIMT) is an important 
marker for early subclinical atherosclerosis. CIMT is also a 
strong predictor for future cardiovascular events in individuals 
RA and non-RA.24,25  In individuals non RA, adiponectin levels 
are inversely related to CIMT, where low adiponectin levels 
will increase progression of atherosclerosis, thereby increasing 
the risk of cardiovascular disease (CVD). Shargorodsky et al 
found that serum levels of adiponectin are associated with 
early atherosclerosis assessed by CIMT in obese patients non-
RA.14 So adiponectin is also an independent predictor marker 
of early subclinical atherosclerosis in obese individuals non-
RA. Measurement technique of Carotid IMT can be considered 
as a valid marker of early atherosclerosis in asymtomatic 
patients and is a predictor of mortality and morbidity of the 
cardiovascular disease.23-25
METHODS
Study Design
The research design was a cross-sectional study design using 
primary data obtained from anamnesis, physical examination, 
and investigation. The study was conducted between January 
until April 2013, at Polyclinic Rheumatology, Department of 
Internal Medicine, Cipto Mangunkusomo Hospital (RSCM), 
Jakarta.
Patients
Total sample consisted of 50 patients with new and old RA 
who have been diagnosed RA based on the ACR 1987/EULAR 
2010 criteria who visited rheumatology outpatient clinic at 
the Cipto Mangunkusomo Hospital (RSCM). Sampling were 
collected using a consecutive sampling method. The inclusion 
criteria were patients with RA who fullfi lled ACR 1987/
EULAR 2010 criteria, age > 16 years when diagnosed and 
are willing to follow the study. The exclusion criteria were 
patients with type 2 diabetes, hypertension, patients with a 
history of myocardial infarction, stroke or peripheral artery 
disease and treatment with ACE-inhibitor drugs.
Assestments
Necessary data were collected by performing anamnesis, 
physical examination, laboratory tests and carotid ultrasound. 
Included in the assessment were clinical variables such as 
age, disease duration of RA, Body Mass Index (BMI), lipid 
profi le, rheumatoid factor levels, levels of anti-CCP, levels 
of anti CRP, and ESR, blood pressure, fasting blood glucose, 
2-hour post-prandial, ECG, and serum adiponectin levels 
examination. The concentration of serum adiponectin [μg/
ml] were measured using Human Adiponectin ELISA kit 
according to the manufacturers’ instructions. The normal value 
of total adiponectin concentration in plasma 3.58 to 9.66 μg/
ml for women and 2.54 to 6.06 for μg/ml for males. Carotid 
ultrasound is done by one person radiologist using ultrasound 
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B-mode brand Philips Sonos 5500. Standard normal values  of 
Carotid Intima-Media Thickness (CIMT) is ≤ 1.0 mm.26
Statistical Analysis
The data collected were analyzed using computer 
applications with SPSS version 15.0. Descriptive and 
analytical data will be presented in the form of text, tables, 
and pictures as appropriate.
 
RESULTS 
Of the 50 subjects involved in this study, 56% (28 patients) 
subjects had high serum adiponectin levels. Mean adiponectin 
levels could not be determined because the data distribution is 
not normal. While the median value is 9.46 μg / ml with the 
lowest levels of 4 μg / ml and the highest levels of 24μg/ml. 
The total of male subject (2 patients) have high adiponectin 
levels.
Bivariate analysis was done to see the correlation of 
independent variabel, namely adiponectin levels with the 
dependent variable, namely atherosclerosis. All variables 
were analyzed had a abnormal distribution, so the Spearman 
correlation statistical test was used. The results of correlation 
test between adiponectin levels and atherosclerosis showed 
a very weak correlation Alt value of p=0706 and r=0.055. 
Furthermore, the relationship of adiponectin levels and 
atherosclerosis were analyzed by age, disease duration, ESR, 
rheumatoid factor, DAS 28, CRP, BMI, and dyslipidemia, but 
none of which showed signifi cant results.   
Figure 2. The relationship between the adiponectin levels and 
average value of atherosclerosis
DISCUSSION
In this study, obtained 28 subjects (56%) had high levels 
of adiponectin. With a higher proportion (56%) indicate that 
adiponectin plays an important role in the pathogenesis of RA.
At the individual non-RA, adiponectin is inversely related 
to atherosclerosis. Adiponectin has been shown to play a 
key role in obesity, infl ammation, insulin resistance and 
atherosclerosis, but little is known about their contribution to 
individual with RA. As shown in this study, the adiponectin 
levels in patients with RA showed no-signifi cant correlation 
with the intima media thickness of the carotid artery. It 
is a marker of early atherosclerosis. The relationship of 
adiponectin and atherosclerosis were then analyzed by age, 
disease duration, ESR, rheumatoid factor, DAS 28, CRP, 
BMI, dyslipidemia, but none of which showed signifi cant 
results. The results of this study have the same results with the 
results obtained by Gonzalez et al.25,27 and Dessein et al.22, that 
there is no correlation between adiponectin and intima media 
thickness of the carotid artery. 
Serum concentration of adiponectin was not associated 
with atherosclerosis and cardiovascular event rates in 
RA.7,20,27,28 It should be noted that in this case, the presence 
of autoimmunity may change the effects of adiponectin on 
metabolic risk and cardiovascular disease.22
So also with the incidence of CVD in RA, because not 
all patients  with RA will experience the same CVD events. 
This difference is thought to be caused by the presence of 
genetic susceptibility to atherosclerosis which may also play 
a role. HLA-DRB1*0404 is a predisposing gene for RA 
and is associated with more severe RA disease. RA patients 
with HLA-DRB1*0404 gene-shared epitope-positive have a 
higher cardiovascular mortality compared with the epitope-
negative.29
Patients with RA had an increased prevalence of premature 
atherosclerosis and insulin resistance, are associated with 
accelerated coronary atherosclerosis.28 Prevalence of CVD 
in RA may be higher than DM type 2.30 This study found no 
correlation between adiponectin with other cardiovascular risk 
factors such as age, disease duration, ESR, rheumatoid factor, 
DAS 28, CRP, BMI, and dyslipidemia. Other researchers also 
found that adiponectin was not correlated with several risk 
factors for atherosclerosis such as coronary calcium scoring28, 
HOMA IR,12.28 total cholesterol, LDL kolesterol levels, 
systolic and diastolic blood pressure12. However, adiponectin 
correlated negatively with high levels of infl ammation and 
plasma glucose.12 Rho et al also found high concentrations 
of adiponectin in patients with RA, but adiponectin was not 
associated with coronary calcifi cation and insulin resistance.28
In another study Gonzalez obtained the different results. 
High levels of infl ammation associated negatively with 
circulating adiponectin, and low adiponectin concentration 
is more correlated independently with an overview of the 
metabolic syndrome (dyslipidemia and high plasma glucose 
levels). These fi ndings are similar to those reported in non-RA 
subjects, and these increase the possibility that adiponectin 
contributes to atherogenesis in RA and subsequently involve 
in cardiovascular disease in patients with RA.12
Adiponectin has been associated as a protective factor for 
atherosclerosis in individual non-RA. However, in this study 
found no relationship between adiponectin and atherosclerosis. 
This may be due in patients with RA, the effect of adiponectin 
in atherosclerosis may be obscured by other infl ammatory 
mediators that have pro-atherogenic effect whose levels are 
elevated in RA.
Adiponectin play an important role in the pathogenesis of 
RA, but plays small role in the pathogenesis of subclinical 
atherosclerosis in RA and inhibition of systemic adiponectin 
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would not change the overall cardiovascular risk in patients 
with RA.22 In the context of adiponectin as a therapeutic target 
for RA, this provides new opportunities for the provision of 
adiponectin inhibitors through the systemic pathways. Because 
adiponectin is not associated with atherosclerosis in patients 
with RA, we don’t need to worry about giving systemic 
inhibitors of adiponectin will eliminate the protective effect 
of adiponectin in the cardiovascular. So that the provision 
of adiponectin inhibitors can be done through the systemic 
pathways.
Another consequence of the results of this study also 
shows that levels of adiponectin have not been able to replace 
the use of ultrasound to measure CIMT as a predictor of 
atherosclerotic events in particular and the incidence of 
cardiovascular disease is common in patients with RA who do 
not exhibit clinical symptoms of cardiovascular disease.
The management to prevent CVD should be supported 
as much as possible. The main cause abnormal accumulation 
of fat mass and adiponectin dysfunction is poor nutrition 
and lifestyle habits, such as overeating and lack of physical 
activity. Therefore, the fi rst approach to manage CVD 
in rheumatic disease is lifestyle modifi cation and other 
therapeutics intervention that lead to decrease of fat mass 
and fat dysfunction to decrease cardiovascular mortality in 
patients with RA.7
From the data above, we need other efforts to prevent 
CVD. Therefore, we also need to know the other risk factors 
that will lead and aggravate cardiovascular disease in RA. In 
general population, cardiovascular mortality the same as RA 
was also associated with CRP and ESR.1 TNF-α and IL-6 is 
a pro-infl ammatory cytokine that also show the independent 
predictive role for cardiovascular events in the future.29 These 
cytokines have an important role in the pathogenesis of RA 
and have high concentration in patients with RA. In addition, 
the duration and disease activity, the involvement of many 
joints, the presence of rheumatoid factor (RF), rheumatoid 
nodules and extra-articular manifestations are also a specifi c 
determinant of CVD events in patients with RA.31 All of this 
suggests that systemic infl ammation is not treated it can cause 
damage before injure the joints. And long-term exposure to 
systemic infl ammation increases the risk of CVD. So the 
use of anti-rheumatic drugs are effective in suppressing the 
infl ammation that will be able to reduce the risk of CVD 
events and one of prevention CVD in RA.1 Besides, it is also 
required close monitoring of serum lipid levels that would 
changes adiponectin production or inhibit its effect in RA.22
Limitations of Research
One of limiting factors in this study was adiponectin which 
had measured in this study are total adiponectin. Whereas 
adiponectin has several isoforms that may have a different 
biological function, and there is the opposite function. 
Although more studies show pro-infl ammatory function of 
adiponectin in patients with RA, but the relationship between 
adiponectin and RA is not fully understood yet. So that further 
studies are needed which refers to the role of adiponectin 
isoforms.
Serum adiponectin levels may not be the same as the joint 
adiponectin levels.20 Adiponectin produced locally by intra-
articular adipocytes, may play a role in the degradation of 
extracellular matrix components.15 These raise an assumption 
that the serum adiponectin levels may not refl ect the actual 
activity of adiponectin in a particular tissue. Alternatively, 
increased production of adiponectin in autoimmune disease 
or in chronic infl ammatory conditions may be secondary to 
infl ammation - due to the catabolic response that occurs in 
RA.15,32,33
CONCLUSION
In this study, we found no statistically signifi cant correlation 
between adiponectin levels with marker of atherosclerosis 
(CIMT) in patients with rheumatoid arthritis
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